@marklewismd @NEJM @MSKCancerCenter I-SPY2 showed MHC-II expression to be predictive of response to immunotherapy for breast cancer patients. This combined with studies with melanoma suggest it may be a better pan-cancer biomarker. https://t.co/6M6H5eo2Z
11 followers
6,874 followers
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. https://t.co/CBqBQtyAZi. #AACRtii21 https://t.co/X2HRObcPGs
369 followers
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/mWw4VYn5ln
7,428 followers
Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer https://t.co/PZPG7KIUhp